Determination of Role of Hyaluronan in Recurrent Renal Stone Formation
Hyaluronan & renal stone formation
Background: Extracorporeal shock wave lithotripsy (ESWL) and percutaneous nephrolithotomy (PCNL) are now widely used to eradicate stones. The present study was conducted to determine role of hyaluronan in recurrent renal stone formation. Subjects and Methods: The study was conducted at Department of Urology, Sapthagiri Institute of Medical Sciences and Research Center, Bangalore between November 2019 to August 2020 on 45 patients of both genders were classified into 3 groups. Group I were normal (15), group II (15) were stone formers and group III (15) were post- treated stone formers. The total urinary glycosaminoglycans, hyaluronan and the proportion of HA in total GAGs were recorded. Results: There were 8 males and 7 females in group I, 6 males and 9 females in group II and 10 males and 5 females in group III. The total urinary glycosaminoglycans (GAGs) concentration in group I was 235.4 µg hexuronate/ mmol creatinine, in group II was 142.3 µg hexuronate/ mmol creatinine and in group III was 108.2 µg hexuronate/ mmol creatinine. The mean hyaluronan level in group I was 812.4 µg hexuronate/ mmol creatinine, in group II was 1725.4 µg hexuronate/ mmol creatinine and in group III was 672.4 µg hexuronate/ mmol creatinine. The mean HA in total GAGs was 0.26% in group I, 0.74% in group II and 1.04% in group III. The difference was significant (P< 0.05). Conclusion: Increased HA production during inflammation of renal epithelial cells in SF do enhance the risk of renal stone formation and an higher HA proportion in total GAGs of both SF and Post-SF indicated that they have a higher risk for the occurrence and recurrence of kidney stone disease.
Alelign T, Petros B. Kidney Stone Disease: An Update on Current Concepts. Adv Urol. 2018;2018:3068365. Available from: https://dx.doi.org/10.1155/2018/3068365.
Liu Y, Chen Y, Liao B, Luo D, Wang K, Li H, et al. Epidemi- ology of urolithiasis in Asia. Asian J Urol.2018;5(4):205–214. Available from: https://dx.doi.org/10.1016/j.ajur.2018.08.007.
Reynolds TM. Chemical pathology clinical investigation and management of nephrolithiasis. J Clin Pathol. 2005;58(2):134–140. Available from: https://dx.doi.org/10.1136/jcp.2004.019588. doi:10.1080/026870300401441.
Gohel MDI, Shum DKY, Tam PC. Electrophoretic separation and characterization of urinary glycosaminoglycans and their roles in urolithiasis. Carbohydr Res. 2007;342:79–86. Avail- able from: https://dx.doi.org/10.1016/j.carres.2006.11.001.
Tiselius HG. A hypothesis of calcium stone formation: an interpretation of stone research during the past decades. Urol Res. 2011;39:231–243. Available from: https://dx.doi.org/10.1007/s00240-010-0349-3.
Borges FT, Michelacci YM, Aguiar JAK, Dalboni MA, Garófalo AS, Schor N. Characterization of glycosaminoglycans in tubular epithelial cells: Calcium oxalate and oxalate ions effects. Kidney Int. 2005;68:1630–1642. Available from: https://dx.doi.org/10.1111/j.1523-1755.2005.00577.x.
Shum DKY, Gohel MDI. Separate Effects of Urinary Chon- droitin Sulphate and Heparan Sulphate on the Crystallization of Urinary Calcium Oxalate: Differences between Stone For- mers and Normal Control Subjects. Clin Sci. 1993;85:33–39. Available from: https://dx.doi.org/10.1042/cs0850033.
Marszalek PE, Oberhauser AF, Li H, Fernandez JM. The Force-Driven Conformations of Heparin Studied with Single Molecule Force Microscopy. Biophys J. 2003;85(4):2696– 2704. Available from: https://dx.doi.org/10.1016/s0006-3495(03)74692-x.
Gohel MDI, Or HYH, Lau MCK, Ng CF. Hyaluronan as a predictive biomarker in recurrent renal stone formers. Int J Urol. 2019;1:29–34. Available from: https://dx.doi.org/10.36811/gju.2019.110005.
Verkoelen CF. Crystal Retention in Renal Stone Disease: A Crucial Role for the Glycosaminoglycan Hyaluronan? J Am Soc Nephrol. 2006;17:1673–1687. Available from: https://dx.doi.org/10.1681/asn.2006010088.
Ebisuno S, Kohjimoto Y, Tamura M, Ohkawa T. Adhesion of Calcium OxalateCrystals to Madin-Darby CanineKidney Cells and Some Effectsof Glycosaminoglycans orCell Injuries. Eur Urol. 1995;28:68–73. Available from: https://dx.doi.org/10.1159/000475023.
Copyright (c) 2020 Author
This work is licensed under a Creative Commons Attribution 4.0 International License.